Johnson & Johnson Stock Price, News & Analysis (NYSE:JNJ)

$146.86 1.10 (0.75 %)
(As of 01/16/2018 04:00 PM ET)
Previous Close$146.86
Today's Range$146.03 - $148.06
52-Week Range$110.76 - $148.06
Volume7.87 million shs
Average Volume5.91 million shs
Market Capitalization$394.54 billion
P/E Ratio25.50
Dividend Yield2.29%
Beta0.8

About Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson logoJohnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Receive JNJ News and Ratings via Email

Sign-up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNYSE:JNJ
CUSIP47816010
Phone+1-732-5242455

Debt

Debt-to-Equity Ratio0.36%
Current Ratio1.32%
Quick Ratio1.02%

Price-To-Earnings

Trailing P/E Ratio25.4965277777778
Forward P/E Ratio20.17
P/E Growth2.75

Sales & Book Value

Annual Sales$71.89 billion
Price / Sales5.49
Cash Flow$8.34 per share
Price / Cash17.61
Book Value$25.88 per share
Price / Book5.67

Profitability

Trailing EPS$5.76
Net Income$16.54 billion
Net Margins21.28%
Return on Equity27.38%
Return on Assets13.20%

Miscellaneous

Employees126,400
Outstanding Shares2,686,520,000

Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson announced a quarterly dividend on Tuesday, January 2nd. Investors of record on Tuesday, February 27th will be given a dividend of $0.84 per share on Tuesday, March 13th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.29%. The ex-dividend date is Monday, February 26th. View Johnson & Johnson's Dividend History.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) announced its earnings results on Tuesday, July, 19th. The company reported $1.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.68 by $0.06. The firm had revenue of $18.50 billion for the quarter, compared to analyst estimates of $17.98 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. View Johnson & Johnson's Earnings History.

When will Johnson & Johnson make its next earnings announcement?

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, January, 23rd 2018. View Earnings Estimates for Johnson & Johnson.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson updated its FY17 earnings guidance on Thursday, December, 21st. The company provided earnings per share guidance of $7.25 - $7.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.28.

Where is Johnson & Johnson's stock going? Where will Johnson & Johnson's stock price be in 2018?

18 equities research analysts have issued 1 year price targets for Johnson & Johnson's shares. Their predictions range from $110.00 to $165.00. On average, they anticipate Johnson & Johnson's share price to reach $145.41 in the next twelve months. View Analyst Ratings for Johnson & Johnson.

What are Wall Street analysts saying about Johnson & Johnson stock?

Here are some recent quotes from research analysts about Johnson & Johnson stock:

  • 1. According to Zacks Investment Research, "Sales in J&J’s domestic Pharma segment decelerated in the first half of 2017 as a number of key growth drivers like Remicade and Concerta are facing competition.  However, sales growth accelerated in Q3 and the positive trend is expected to continue in Q4. We believe that new products in all segments, label expansion of drugs like Imbruvica and Darzalex and contribution from recent acquisitions - mainly Actelion – can support top-line growth.  Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. J&J’s shares have outperformed the industry this year so far.  However, headwinds like generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment is also a concern." (12/12/2017)
  • 2. BTIG Research analysts commented, "Yesterday, we attended JNJ’s Pharma day held in New Brunswick, NJ. The overarching theme of the day was the expectation that the Pharma business outgrows the IMS projected ~5% 5-year CAGR for branded drugs. Our model is significantly below such expectations, as we have reported growth of ~6.5% during 2017 falling to ~3.6% in 2018 and essentially flat through 2020. Our numbers may prove conservative given that we do not currently include new drug launches of esketamine, guselkumab and sirukumab. We remain Neutral, as we think that the Oncology landscape is becoming more complicated and the Immunology portfolio may underperform internal expectations as a new class of oral drugs comes to market." (5/21/2017)
  • 3. UBS Group AG analysts commented, "After making appropriate adjustments for year-over-year shipping day differences, JNJ's Q4 sales were up an impressive 9.5% in the U.S., and up 7.6% CC WW. Initial 2017 outlook calls for sales of $74.1-74.8 bil (up 4-5% CC) and EPS of $6.93-7.08 (including the AMO deal). As previewed, the guided range reflects greater impact from FX, and by our estimation a degree of conservatism. Given the continued strong growth of key Pharma franchises, management's potential to drive stable to improving margins, the ~$2.5 bil remaining repurchase authorization and other factors, we see flex and potential upside to management's initial 2017 outlook. We reiterate our Buy rating on top large-cap diversified pick JNJ, trimming our target from $142 to $141 due primarily to the ~$4.3 bil cash outlay for AMO, expected to close in 1Q17." (1/25/2017)

Who are some of Johnson & Johnson's key competitors?

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the folowing people:

  • Alex Gorsky, Chairman of the Board, Chief Executive Officer (Age 56)
  • Dominic J. Caruso, Chief Financial Officer, Executive Vice President (Age 59)
  • Peter M. Fasolo Ph.D., Chief Human Resource Officer, Executive Vice President (Age 54)
  • Paulus A. Stoffels, Executive Vice President, Chief Scientific Officer (Age 55)
  • Michael H. Ullmann, Executive Vice President, General Counsel (Age 58)
  • Joaquin Duato, Executive Vice President, Worldwide Chairman - Pharmaceuticals (Age 54)
  • Jorge S. Mesquita, Executive Vice President, Worldwide Chairman - Consumer (Age 55)
  • Sandra E. Peterson, Executive Vice President - Group Worldwide Chairman (Age 58)
  • Joseph Wolk, Vice President - Investor Relations
  • Anne M. Mulcahy, Lead Independent Director (Age 64)

Who owns Johnson & Johnson stock?

Johnson & Johnson's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Hexavest Inc. (0.07%), Bristol John W & Co. Inc. NY (0.06%), Nisa Investment Advisors LLC (0.04%), Confluence Investment Management LLC (0.04%), DnB Asset Management AS (0.03%) and KAMES CAPITAL plc (0.03%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso, Gary J Pruden, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.

Who sold Johnson & Johnson stock? Who is selling Johnson & Johnson stock?

Johnson & Johnson's stock was sold by a variety of institutional investors in the last quarter, including DnB Asset Management AS, Exxonmobil Investment Management Inc. TX, Country Trust Bank, Sit Investment Associates Inc., Bristol John W & Co. Inc. NY, KAMES CAPITAL plc, Beacon Financial Group and Nisa Investment Advisors LLC. Company insiders that have sold Johnson & Johnson company stock in the last year include Dominic J Caruso and Paulus Stoffels. View Insider Buying and Selling for Johnson & Johnson.

Who bought Johnson & Johnson stock? Who is buying Johnson & Johnson stock?

Johnson & Johnson's stock was purchased by a variety of institutional investors in the last quarter, including Hexavest Inc., Sawyer & Company Inc, Stock Yards Bank & Trust Co., Stillwater Capital Advisors LLC, White Lighthouse Investment Management Inc., Broadleaf Partners LLC, Hefty Wealth Partners and Acropolis Investment Management LLC. View Insider Buying and Selling for Johnson & Johnson.

How do I buy Johnson & Johnson stock?

Shares of Johnson & Johnson can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Johnson & Johnson's stock price today?

One share of Johnson & Johnson stock can currently be purchased for approximately $146.86.

How big of a company is Johnson & Johnson?

Johnson & Johnson has a market capitalization of $394.54 billion and generates $71.89 billion in revenue each year. The company earns $16.54 billion in net income (profit) each year or $5.76 on an earnings per share basis. Johnson & Johnson employs 126,400 workers across the globe.

How can I contact Johnson & Johnson?

Johnson & Johnson's mailing address is 1 Johnson And Johnson Plz, NEW BRUNSWICK, NJ 08933-0001, United States. The company can be reached via phone at +1-732-5242455.


MarketBeat Community Rating for Johnson & Johnson (JNJ)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  512 (Vote Outperform)
Underperform Votes:  615 (Vote Underperform)
Total Votes:  1,127
MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Johnson & Johnson (NYSE:JNJ) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.282.332.252.53
Ratings Breakdown: 4 Sell Rating(s)
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
4 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
7 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $145.41$145.12$141.32$135.19
Price Target Upside: 0.44% downside2.82% upside0.45% upside0.02% downside

Johnson & Johnson (NYSE:JNJ) Consensus Price Target History

Price Target History for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/12/2018Wells Fargo & CoReiterated RatingOutperform -> Outperform$155.00 -> $160.00LowView Rating Details
1/9/2018Royal Bank of CanadaReiterated RatingBuyLowView Rating Details
1/2/2018JPMorgan Chase & Co.DowngradeOverweight -> NeutralLowView Rating Details
12/12/2017BMO Capital MarketsBoost Price TargetOutperform$161.00MediumView Rating Details
10/23/2017CitigroupBoost Price TargetBuy$140.00 -> $149.00N/AView Rating Details
10/19/2017Credit Suisse GroupSet Price TargetOutperform$147.00 -> $154.00N/AView Rating Details
10/16/2017Jefferies GroupBoost Price TargetBuy$157.00 -> $160.00N/AView Rating Details
10/18/2017BarclaysBoost Price TargetEqual Weight$140.00 -> $148.00N/AView Rating Details
10/18/2017CowenReiterated RatingOutperform$147.00 -> $155.00N/AView Rating Details
10/18/2017Morgan StanleyReiterated RatingHold$140.00 -> $145.00N/AView Rating Details
10/18/2017ArgusBoost Price TargetBuy -> Positive$145.00 -> $165.00N/AView Rating Details
10/18/2017Stifel NicolausBoost Price TargetHold -> Hold$140.00 -> $142.00N/AView Rating Details
10/18/2017Leerink SwannReiterated RatingOutperform -> Outperform$150.00 -> $165.00N/AView Rating Details
10/4/2017Piper Jaffray CompaniesReiterated RatingHold$120.00LowView Rating Details
9/20/2017Goldman Sachs GroupDowngradeNeutral -> Sell$125.00 -> $130.00LowView Rating Details
7/21/2017Alembic Global AdvisorsDowngradeNeutral -> UnderweightLowView Rating Details
7/21/2017Atlantic SecuritiesDowngradeNeutral -> Underweight$113.00LowView Rating Details
7/21/2017BTIG ResearchDowngradeNeutral -> Sell$110.00LowView Rating Details
11/28/2016Bank of AmericaReiterated RatingHold$126.00N/AView Rating Details
10/23/2016Societe GeneraleReiterated RatingHold$116.00N/AView Rating Details
8/19/2016Deutsche BankReiterated RatingBuy$142.00N/AView Rating Details
5/20/2016Raymond James FinancialReiterated RatingOutperform$120.00N/AView Rating Details
5/20/2016Standpoint ResearchInitiated CoverageSell$94.00N/AView Rating Details
1/27/2016Independent ResearchSet Price TargetNeutral$108.00N/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Johnson & Johnson (NYSE:JNJ) Earnings History and Estimates Chart

Earnings by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE JNJ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/23/2018$1.72N/AView Earnings Details
10/17/2017Q3 2017$1.80$1.90$19.29 billion$19.65 billionViewN/AView Earnings Details
7/18/2017Q2 2017$1.79$1.83$18.94 billion$18.84 billionViewN/AView Earnings Details
4/18/2017Q1 17$1.77$1.83$18.02 billion$17.77 billionViewN/AView Earnings Details
1/24/2017Q416$1.56$1.58$18.28 billion$18.10 billionViewN/AView Earnings Details
10/18/2016Q316$1.65$1.68$17.71 billion$17.80 billionViewListenView Earnings Details
7/19/2016Q216$1.68$1.74$17.98 billion$18.50 billionViewListenView Earnings Details
4/19/2016Q116$1.65$1.68$17.50 billion$17.50 billionViewListenView Earnings Details
1/26/2016Q415$1.42$1.44$17.88 billion$17.80 billionViewListenView Earnings Details
10/13/2015Q315$1.45$1.49$17.47 billion$17.10 billionViewListenView Earnings Details
7/14/2015Q215$1.69$1.71$17.76 billion$17.80 billionViewListenView Earnings Details
4/14/2015Q115$1.54$1.56$17.31 billion$17.37 billionViewListenView Earnings Details
1/20/2015Q414$1.25$1.27$18.59 billion$18.30 billionViewListenView Earnings Details
10/14/2014Q314$1.42$1.50$18.41 billion$18.50 billionViewListenView Earnings Details
7/15/2014Q214$1.54$1.66$18.86 billion$19.50 billionViewN/AView Earnings Details
4/15/2014Q114$1.48$1.54$18.00 billion$18.10 billionViewN/AView Earnings Details
1/21/2014Q413$1.20$1.24$17.95 billion$18.40 billionViewN/AView Earnings Details
10/15/2013Q313$1.32$1.36$17.46 billion$17.60 billionViewN/AView Earnings Details
7/16/2013Q2 2013$1.39$1.48$17.71 billion$17.90 billionViewN/AView Earnings Details
4/16/2013Q1 2013$1.41$1.44$17.46 billion$17.50 billionViewN/AView Earnings Details
1/22/2013Q4 2012$1.17$1.19$17.67 billion$17.60 billionViewN/AView Earnings Details
10/16/2012$1.21$1.25ViewN/AView Earnings Details
7/17/2012$1.29$1.30ViewN/AView Earnings Details
4/17/2012$1.34$1.37ViewN/AView Earnings Details
1/24/2012$1.09$1.13ViewN/AView Earnings Details
10/18/2011$1.21$1.24ViewN/AView Earnings Details
7/19/2011$1.24$1.28ViewN/AView Earnings Details
4/19/2011$1.26$1.35ViewN/AView Earnings Details
1/25/2011$1.03$1.03ViewN/AView Earnings Details
10/19/2010Q3 2010$1.15$1.23ViewN/AView Earnings Details
7/20/2010Q2 2010$1.21$1.21ViewN/AView Earnings Details
4/20/2010Q1 2010$1.27$1.29ViewN/AView Earnings Details
1/26/2010Q4 2009$0.97$1.02ViewN/AView Earnings Details
10/13/2009Q3 2009$1.13$1.20ViewN/AView Earnings Details
7/14/2009Q2 2009$1.12$1.15ViewN/AView Earnings Details
4/14/2009Q1 2009$1.21$1.26ViewN/AView Earnings Details
1/20/2009Q4 2008$0.92$0.94ViewN/AView Earnings Details
10/14/2008Q3 2008$1.11$1.17ViewN/AView Earnings Details
7/15/2008Q2 2008$1.13$1.18ViewN/AView Earnings Details
4/15/2008Q1 2008$1.20$1.26ViewN/AView Earnings Details
1/22/2008Q4 2007$0.86$0.88ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Johnson & Johnson (NYSE:JNJ) Earnings Estimates

2018 EPS Consensus Estimate: $7.99
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$1.99$1.99$1.99
Q2 20181$2.01$2.01$2.01
Q3 20181$2.18$2.18$2.18
Q4 20181$1.81$1.81$1.81
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Johnson & Johnson (NYSE:JNJ) Dividend Information

Next Dividend:3/13/2018
Annual Dividend:$3.36
Dividend Yield:2.29%
Dividend Growth:6.40% (3 Year Average)
Payout Ratio:58.33% (Trailing 12 Months of Earnings)
46.15% (Based on This Year's Estimates)
42.80% (Based on Next Year's Estimates)
Track Record:55 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/2/2018quarterly$0.842.39%2/26/20182/27/20183/13/2018
10/19/2017quarterly$0.842.37%11/27/201711/28/201712/12/2017
7/17/2017quarterly$0.842.5%8/25/20178/29/20179/12/2017
4/27/2017quarterly$0.842.72%5/25/20175/30/20176/13/2017
1/3/2017quarterly$0.802.77%2/24/20172/28/20173/14/2017
10/20/2016quarterly$0.8011/18/201611/22/201612/6/2016
7/18/2016quarterly$0.808/19/20168/23/20169/6/2016
4/28/2016quarterly$0.805/20/20165/24/20166/7/2016
1/4/2016quarterly$0.752/19/20162/23/20163/8/2016
10/22/2015quarterly$0.7511/20/201511/24/201512/8/2015
7/20/2015quarterly$0.758/21/20158/25/20159/8/2015
4/23/2015quarterly$0.752.97%5/21/20155/26/20156/9/2015
1/5/2015quarterly$0.702.71%2/20/20152/24/20153/10/2015
10/16/2014quarterly$0.702.89%11/21/201411/25/201412/9/2014
7/21/2014quarterly$0.702.73%8/22/20148/26/20149/9/2014
4/24/2014quarterly$0.702.81%5/22/20145/27/20146/10/2014
1/2/2014quarterly$0.662.87%2/21/20142/25/20143/11/2014
10/17/2013quarterly$0.662.88%11/22/201311/26/201312/10/2013
7/15/2013quarterly$0.662.92%8/23/20138/27/20139/10/2013
4/25/2013quarterly$0.663.1%5/23/20135/28/20136/11/2013
1/2/2013quarterly$0.613.45%2/22/20132/26/20133/12/2013
(Data available from 1/1/2013 forward)

Insider Trades

Johnson & Johnson (NYSE JNJ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.19%
Institutional Ownership Percentage: 65.71%
Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)
Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE JNJ) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/24/2017Paulus StoffelsVPSell102,692$133.14$13,672,412.88230,342View SEC Filing  
7/20/2017Dominic J CarusoVPSell82,591$136.72$11,291,841.52226,693View SEC Filing  
2/15/2017Paulus StoffelsVPSell22,000$117.29$2,580,380.00127,650View SEC Filing  
10/21/2016Charles PrinceDirectorBuy875$114.11$99,846.2526,520View SEC Filing  
7/26/2016Dominic J CarusoVPSell41,146$125.01$5,143,661.46157,819View SEC Filing  
7/22/2016Ronald A KapustaCAOSell2,935$125.01$366,904.3528,660View SEC Filing  
6/7/2016Gary J PrudenVPSell9,735$116.03$1,129,552.0543,630View SEC Filing  
6/7/2016Ronald A KapustaCAOSell3,000$115.79$347,370.0028,725View SEC Filing  
5/10/2016Ronald A KapustaCAOSell3,957$114.77$454,144.8929,682View SEC Filing  
2/17/2016Paulus StoffelsinsiderSell125,000$102.43$12,803,750.00122,543View SEC Filing  
2/3/2016Peter FasoloVPSell151,385$104.12$15,762,206.2037,735View SEC Filing  
10/23/2015Ronald A. KapustaCAOSell6,239$99.68$621,903.5220,803View SEC Filing  
6/2/2015Charles PrinceDirectorBuy2,500$99.22$248,050.00View SEC Filing  
4/28/2015Paulus StoffelsInsiderSell187,250$100.73$18,861,692.50View SEC Filing  
9/10/2014James CullenDirectorSell2,446$104.12$254,677.52View SEC Filing  
5/5/2014Stephen CosgroveInsiderSell22,000$100.05$2,201,100.0090,294View SEC Filing  
3/14/2014Peter FasoloVPSell6,824$93.15$635,655.6015,647View SEC Filing  
8/14/2013Stephen CosgroveInsiderSell17,200$91.39$1,571,908.0088,159View SEC Filing  
8/5/2013Michael UllmannVPSell16,140$93.68$1,511,995.2055,427View SEC Filing  
7/25/2013Paulus StoffelsInsiderSell45,440$92.40$4,198,656.00View SEC Filing  
7/18/2013Dominic J CarusoCFOSell30,000$90.31$2,709,300.00View SEC Filing  
11/12/2012James CullenDirectorSell13,900$69.70$968,830.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Johnson & Johnson (NYSE JNJ) News Headlines

Source:
DateHeadline
Is Johnson & Johnson a Buy? - Motley FoolIs Johnson & Johnson a Buy? - Motley Fool
www.fool.com - January 16 at 6:04 AM
Johnson & Johnson (JNJ) Scheduled to Post Quarterly Earnings on TuesdayJohnson & Johnson (JNJ) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - January 16 at 2:50 AM
Is Johnson & Johnson a Buy?Is Johnson & Johnson a Buy?
www.fool.com - January 15 at 11:28 PM
Vetr Upgrades Johnson & Johnson (JNJ) to BuyVetr Upgrades Johnson & Johnson (JNJ) to Buy
www.americanbankingnews.com - January 14 at 8:50 PM
Trump looks to revamp major Medicaid requirementsTrump looks to revamp major Medicaid requirements
finance.yahoo.com - January 13 at 3:17 PM
Johnson & Johnson (JNJ) Stock Rating Reaffirmed by Wells Fargo & CoJohnson & Johnson (JNJ) Stock Rating Reaffirmed by Wells Fargo & Co
www.americanbankingnews.com - January 12 at 11:16 PM
Johnson & Johnson (JNJ) PT Raised to $160 at Wells Fargo on Q4 Earnings Preview; Potential Upside to 2018 ... - StreetInsider.comJohnson & Johnson (JNJ) PT Raised to $160 at Wells Fargo on Q4 Earnings Preview; 'Potential Upside to 2018 ... - StreetInsider.com
www.streetinsider.com - January 12 at 3:17 PM
Johnson & Johnson (JNJ) Reports First Patient Enrolled in ... - StreetInsider.comJohnson & Johnson (JNJ) Reports First Patient Enrolled in ... - StreetInsider.com
www.streetinsider.com - January 12 at 5:52 AM
Changes to Federal Tax Law Just What the Doctor Ordered for Healthcare FirmsChanges to Federal Tax Law Just What the Doctor Ordered for Healthcare Firms
finance.yahoo.com - January 12 at 5:52 AM
Johnson & Johnson (JNJ) Reports First Patient Enrolled in WaveCrest Investigational Device Exemption TrialJohnson & Johnson (JNJ) Reports First Patient Enrolled in WaveCrest Investigational Device Exemption Trial
www.streetinsider.com - January 11 at 3:18 PM
Pharmas Tax-Cut Plans Look Pretty DullPharma's Tax-Cut Plans Look Pretty Dull
finance.yahoo.com - January 11 at 3:18 PM
Johnson & Johnson chief Gorsky thumbs up new tax law, plans ... - Seeking AlphaJohnson & Johnson chief Gorsky thumbs up new tax law, plans ... - Seeking Alpha
seekingalpha.com - January 11 at 5:58 AM
JNJ CEO: DACA important at a personal levelJNJ CEO: DACA important at a personal level
finance.yahoo.com - January 11 at 5:58 AM
JNJ employee expresses gratitude to CEO Alex Gorsky for D...JNJ employee expresses gratitude to CEO Alex Gorsky for D...
finance.yahoo.com - January 11 at 5:58 AM
Putting On The Brakes: Rally Takes Breather As Bond Yields Hit 10-Month HighPutting On The Brakes: Rally Takes Breather As Bond Yields Hit 10-Month High
finance.yahoo.com - January 10 at 3:18 PM
Why JNJs Stock Has Healthy Gains AheadWhy JNJ's Stock Has Healthy Gains Ahead
finance.yahoo.com - January 10 at 3:18 PM
Bayer, J&J win reversal of $28 million verdict in Xarelto lawsuit - ReutersBayer, J&J win reversal of $28 million verdict in Xarelto lawsuit - Reuters
www.reuters.com - January 10 at 6:07 AM
Johnson & Johnson Wants to Create a Crisis -- and Thats Great for Investors - Motley FoolJohnson & Johnson Wants to Create a Crisis -- and That's Great for Investors - Motley Fool
www.fool.com - January 10 at 6:07 AM
Bayer, J&J win reversal of $28 million verdict in Xarelto lawsuitBayer, J&J win reversal of $28 million verdict in Xarelto lawsuit
finance.yahoo.com - January 10 at 6:07 AM
3 Dividend Stocks That Cut Bigger Checks Than Johnson & Johnson3 Dividend Stocks That Cut Bigger Checks Than Johnson & Johnson
www.fool.com - January 9 at 9:02 PM
Noteworthy Tuesday Option Activity: AGN, JNJ, HONNoteworthy Tuesday Option Activity: AGN, JNJ, HON
www.nasdaq.com - January 9 at 3:17 PM
Incentives, new jobs plan gets green light for Lake Nonas Johnson & Johnson instituteIncentives, new jobs plan gets green light for Lake Nona's Johnson & Johnson institute
www.bizjournals.com - January 9 at 3:17 PM
Dow Movers: NKE, JNJDow Movers: NKE, JNJ
www.msn.com - January 9 at 3:17 PM
2018 J.P. Morgan Healthcare Conference Roundup2018 J.P. Morgan Healthcare Conference Roundup
finance.yahoo.com - January 9 at 3:17 PM
Johnson & Johnson CEO: We should all be acting like Amazo...Johnson & Johnson CEO: We should all be acting like Amazo...
finance.yahoo.com - January 9 at 3:17 PM
Stock Indexes Hit New Highs; Why J&J Is HotStock Indexes Hit New Highs; Why J&J Is Hot
finance.yahoo.com - January 9 at 3:17 PM
Geron Corporation's 13% Drop in 2017, ExplainedGeron Corporation's 13% Drop in 2017, Explained
finance.yahoo.com - January 9 at 3:17 PM
Markets Right Now: Banks, health care leads gains for stocksMarkets Right Now: Banks, health care leads gains for stocks
finance.yahoo.com - January 9 at 3:17 PM
Judge urges action on '100 percent manmade' opioid crisisJudge urges action on '100 percent manmade' opioid crisis
finance.yahoo.com - January 9 at 3:17 PM
Markets Right Now: Health care leads early gains for stocksMarkets Right Now: Health care leads early gains for stocks
marketbeat.com - January 9 at 9:52 AM
Johnson & Johnson Wants to Create a Crisis -- and Thats Great for InvestorsJohnson & Johnson Wants to Create a Crisis -- and That's Great for Investors
www.fool.com - January 9 at 8:51 AM
Johnson & Johnson (JNJ) Management Presents at 36th Annual ... - Seeking AlphaJohnson & Johnson (JNJ) Management Presents at 36th Annual ... - Seeking Alpha
seekingalpha.com - January 9 at 6:34 AM
Johnson & Johnson: A Good Value In This Overheated Market ... - Seeking AlphaJohnson & Johnson: A Good Value In This Overheated Market ... - Seeking Alpha
seekingalpha.com - January 9 at 6:34 AM
Biotech and pharma firms like the US tax law — but not because of their new ratesBiotech and pharma firms like the US tax law — but not because of their new rates
finance.yahoo.com - January 9 at 6:34 AM
Drug Industry Isn’t Giving Up on Alzheimer’sDrug Industry Isn’t Giving Up on Alzheimer’s
finance.yahoo.com - January 9 at 6:34 AM
Celgene deal could be the first of many for biopharma as new tax law frees up cashCelgene deal could be the first of many for biopharma as new tax law frees up cash
finance.yahoo.com - January 8 at 3:18 PM
Here's Why Insulet Corporation Jumped TodayHere's Why Insulet Corporation Jumped Today
finance.yahoo.com - January 8 at 3:18 PM
IVV, JPM, JNJ, XOM: Large Inflows Detected at ETFIVV, JPM, JNJ, XOM: Large Inflows Detected at ETF
www.nasdaq.com - January 8 at 11:16 AM
Pfizer to Stall R&D for Alzheimer's/Parkinson's, Cut JobsPfizer to Stall R&D for Alzheimer's/Parkinson's, Cut Jobs
finance.yahoo.com - January 8 at 11:16 AM
Research Analysts Set Expectations for Johnson & Johnsons FY2017 Earnings (JNJ)Research Analysts Set Expectations for Johnson & Johnson's FY2017 Earnings (JNJ)
www.americanbankingnews.com - January 8 at 2:28 AM
Johnson & Johnson (JNJ) PT Raised to $162 at Jefferies - StreetInsider.comJohnson & Johnson (JNJ) PT Raised to $162 at Jefferies - StreetInsider.com
www.streetinsider.com - January 6 at 7:22 AM
A Look At Johnson & Johnsons Medical Devices SegmentA Look At Johnson & Johnson's Medical Devices Segment
www.nasdaq.com - January 5 at 3:19 PM
Johnson & Johnson’s Profit Margins in 3Q17Johnson & Johnson’s Profit Margins in 3Q17
finance.yahoo.com - January 5 at 3:19 PM
How the Health Care Sector Performed in 2017How the Health Care Sector Performed in 2017
finance.yahoo.com - January 5 at 3:19 PM
Analysts’ Estimates for Johnson & JohnsonAnalysts’ Estimates for Johnson & Johnson
finance.yahoo.com - January 5 at 3:19 PM
Johnson & Johnson changes hiring plan for regional HQ in Lake NonaJohnson & Johnson changes hiring plan for regional HQ in Lake Nona
finance.yahoo.com - January 5 at 3:19 PM
BioCorRx Retains Regulatory Drug Expert Priya Jambhekar and CMC Expert Bruce Firestone, Ph.DBioCorRx Retains Regulatory Drug Expert Priya Jambhekar and CMC Expert Bruce Firestone, Ph.D
feeds.benzinga.com - January 5 at 12:13 PM
The Slow Push Upward Continues for Johnson & Johnson StockThe Slow Push Upward Continues for Johnson & Johnson Stock
investorplace.com - January 5 at 10:01 AM
The Slow Push Upward Continues for Johnson & Johnson StockThe Slow Push Upward Continues for Johnson & Johnson Stock
investorplace.com - January 5 at 9:25 AM
Johnson & Johnson Innovation Champions Leading Edge Science with 15 New Collaborations with Potential to Impact Patients LivesJohnson & Johnson Innovation Champions Leading Edge Science with 15 New Collaborations with Potential to Impact Patients' Lives
www.prnewswire.com - January 5 at 7:52 AM

SEC Filings

Johnson & Johnson (NYSE:JNJ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Johnson & Johnson (NYSE:JNJ) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Johnson & Johnson (NYSE JNJ) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.